Objective To evaluate the clinical effect of tazarotene and betamethasone dipropionate cream in the treatment of chronic plaque psoriasis. Methods A total of 62 patients with chronic plaque psoriasis treated in our hospital from January 2020 to August 2021 were selected and randomly divided into observation group and control group, with 31 cases in each group. The observation group was treated with tazarotene and betamethasone dipropionate cream and the control group was treated with calcipotriol ointment. The overall assessment (PGA), psoriasis lesion area and severity index (PASI), symptom score, skin disease quality of life index (DLQI) and medication safety of the two groups were compared. Results The PGA, PASI, symptom score, DLQI and inflammatory factors in the observation group were lower than those in the control group (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion Tazarotene and betamethasone dipropionate cream has less adverse reactions in patients with chronic plaque psoriasis, which can reduce the expression of inflammatory factors, quickly relieve symptoms and improve the quality of life of patients.